Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 20124139)

1.

Effects of metformin on energy intake and satiety in obese children.

Adeyemo MA, McDuffie JR, Kozlosky M, Krakoff J, Calis KA, Brady SM, Yanovski JA.

Diabetes Obes Metab. 2015 Apr;17(4):363-70. doi: 10.1111/dom.12426. Epub 2015 Jan 11.

2.
3.

The therapy of insulin resistance in other diseases besides type 2 diabetes.

Pala L, Barbaro V, Dicembrini I, Rotella CM.

Eat Weight Disord. 2014;19(3):275-83. doi: 10.1007/s40519-014-0139-y. Epub 2014 Jul 29. Review.

4.

An evolving scientific basis for the prevention and treatment of pediatric obesity.

Katzmarzyk PT, Barlow S, Bouchard C, Catalano PM, Hsia DS, Inge TH, Lovelady C, Raynor H, Redman LM, Staiano AE, Spruijt-Metz D, Symonds ME, Vickers M, Wilfley D, Yanovski JA.

Int J Obes (Lond). 2014 Jul;38(7):887-905. doi: 10.1038/ijo.2014.49. Epub 2014 Mar 25. Review.

PMID:
24662696
5.

The "slower" the better.

Pala L, Rotella CM.

J Endocrinol Invest. 2014 May;37(5):497-8. doi: 10.1007/s40618-014-0065-x. Epub 2014 Mar 22. No abstract available.

6.

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.

Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ.

JAMA Pediatr. 2013 Apr;167(4):355-60. doi: 10.1001/jamapediatrics.2013.1045.

7.

Treatment of obesity in children and adolescents.

Matson KL, Fallon RM.

J Pediatr Pharmacol Ther. 2012 Jan;17(1):45-57. doi: 10.5863/1551-6776-17.1.45.

8.

Pharmacotherapy for childhood obesity: present and future prospects.

Sherafat-Kazemzadeh R, Yanovski SZ, Yanovski JA.

Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28. Review.

9.

Assessment of metformin as an additional treatment to therapeutic lifestyle changes in pediatric patients with metabolic syndrome.

Raub RM, Goldberg SJ.

Cholesterol. 2012;2012:961410. doi: 10.1155/2012/961410. Epub 2012 Jul 4.

10.

Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.

Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Merinbaum D, Weltman A, Damaso L, Balagopal P.

J Pediatr Endocrinol Metab. 2012;25(1-2):33-40.

11.

Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.

Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ.

Obesity (Silver Spring). 2012 Feb;20(2):364-70. doi: 10.1038/oby.2011.337. Epub 2011 Nov 10.

12.

Pediatric obesity: etiology and treatment.

Crocker MK, Yanovski JA.

Pediatr Clin North Am. 2011 Oct;58(5):1217-40, xi. doi: 10.1016/j.pcl.2011.07.004. Review.

13.

Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years.

Glueck CJ, Morrison JA, Daniels S, Wang P, Stroop D.

J Pediatr. 2011 Aug;159(2):308-13.e2. doi: 10.1016/j.jpeds.2011.01.018. Epub 2011 Mar 1.

14.

AMPK as Target for Intervention in Childhood and Adolescent Obesity.

Rojas J, Arraiz N, Aguirre M, Velasco M, Bermúdez V.

J Obes. 2011;2011:252817. doi: 10.1155/2011/252817. Epub 2010 Dec 22.

15.

Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.

Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA.

Diabetes. 2011 Feb;60(2):477-85. doi: 10.2337/db10-1185. Epub 2011 Jan 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk